Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Revenue of Sight Sciences, Inc. (SGHT)
Revenue in 2023 (TTM): $81.06 M
According to Sight Sciences, Inc.'s latest financial reports the company's current revenue (TTM) is $81.06 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Sight Sciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $81.06 M | $69.18 M | $-56,660,000 | $-55,437,000 | $-55,547,000 |
| 2022 | $71.33 M | $58.97 M | $-81,729,000 | $-86,195,000 | $-86,242,000 |
| 2021 | $48.96 M | $40.35 M | $-58,406,000 | $-62,772,000 | $-62,960,000 |
| 2020 | $27.64 M | $18.43 M | $-31,675,000 | $-34,632,000 | $-34,693,000 |
| 2019 | $23.35 M | $16.8 M | $-23,605,000 | $-25,861,000 | $-25,869,000 |
| 2018 | $7.53 M | $5.19 M | $-14,233,000 | $-14,296,000 | $-14,290,000 |